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Abstract
Background—In high-income countries, depression is prevalent in HIV patients and is
associated with lower medication adherence and clinical outcomes. Emerging evidence from low-
income countries supports similar relationships. Yet little research has validated rapid depression
screening tools integrated into routine HIV clinical care.
Methods—Using qualitative methods, we adapted the Patient Health Questionnaire-9 (PHQ-9)
depression screening instrument for use with Cameroonian patients. We then conducted a cross-
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sectional validity study comparing an interviewer-administered PHQ-9 to the reference standard
Composite International Diagnostic Interview in 400 patients on antiretroviral therapy attending a
regional HIV treatment center in Bamenda, Cameroon.
Results—The prevalence of major depressive disorder (MDD) in the past month was 3% (n=11
cases). Using a standard cutoff score of ≥10 as a positive depression screen, the PHQ-9 had
estimated sensitivity of 27% (95% confidence interval: 6–61%) and specificity of 94% (91–96%),
corresponding to positive and negative likelihood ratios of 4.5 and 0.8. There was little evidence
of variation in specificity by gender, number of HIV symptoms, or result of a dementia screen.
Limitations—The low prevalence of MDD yielded very imprecise sensitivity estimates.
Although the PHQ-9 was developed as a self-administered tool, we assessed an interviewer-
administered version due to the literacy level of the target population.
Conclusion—The PHQ-9 demonstrated high specificity but apparently low sensitivity for
detecting MDD in this sample of HIV patients in Cameroon. Formative work to define the
performance of proven screening tools in new settings remains important as research on mental
health expands in low-income countries.
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Introduction
In high-income nations, depression in HIV patients has received much attention as a highly
prevalent comorbidity and a predictor of reduced antiretroviral (ARV) medication
adherence, higher transmission risk behaviors, and poorer clinical outcomes.1–3 As access to
HIV clinical care and ARVs expands in sub-Saharan Africa,4 increasing attention has been
focused on the prevalence and consequences of depression for HIV-infected patients in these
settings.3 Evidence to date suggests that in sub-Saharan Africa, as in other parts of the
world, the prevalence of depression is higher in HIV patients than in the general population
and that depression is associated with worse ARV adherence and HIV clinical outcomes.2,5
In order to respond to the potential negative impact of depression on HIV clinical care, HIV
clinical settings require rapid, validated screening tools to identify patients with a likely
depressive disorder. Brief depression screening tools such as the Patient Health
Questionnaire-9 (PHQ-9)6 are becoming widely used in the United States and Europe, but
these tools were generally developed for self-administration by a literate population. Few
studies7 have been conducted in African countries validating such tools against reference
standard diagnostic assessments, especially in low-literacy populations, or have considered
their application in HIV-infected populations specifically.8
Accordingly, we undertook to validate the PHQ-9 as a depression screening tool compared
to the internationally calibrated Composite International Diagnostic Interview (CIDI) at a
regional hospital serving a predominantly poor and low-literacy HIV patient population in
the Northwest Region of Cameroon. Cameroon is a country of approximately 20 million
people in Central Africa9 with an estimated HIV prevalence rate of 5.3%.10
Methods
Ethical approvals
This study was approved by the Cameroon National Ethics Committee (No. 111/CNE/SE/
09), the University of North Carolina at Chapel Hill's Biomedical Institutional Review
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Board (# 09-0852) and the Duke University Health System IRB (# Pro00016937). The study
also received administrative approval from the Ministry of Public Health in Cameroon.
Sample
We conducted a cross-sectional validation study to compare depression screening results
from the PHQ-9 to a reference standard tool for depression diagnosis among HIV-positive
patients on antiretroviral therapy (ART) and attending the Bamenda Regional Hospital
AIDS Treatment Center (BRHATC) in Cameroon. The BRHATC is a health facility
dedicated to the care of HIV-positive patients, the vast majority of whom are on ART. The
center provides care to over 4,000 patients annually. Patients were eligible if they were HIV-
infected, on antiretroviral therapy ART, were attending the BRHATC for any service
(including counseling, clinical follow-up or drug refill), spoke English, were ages 18–55,
and were willing to provide informed consent. We excluded patients >55 years because the
present study was to lay the groundwork for a medication trial which would exclude patients
>55 years for safety reasons. Patients who could not give consent or refused to give consent
were excluded. Although more than 30 local languages exist, English is the language used
for regular clinical care in the BRHATC and throughout the Northwest Region of
Cameroon; more than 95% of clinic attendees can communicate effectively in English. Each
participant could be eligible only once during the study period.
Our sampling goal was to recruit a study sample representative of HIV-positive patients
receiving ART at BRHATC. In the absence of a daily patient register to provide a sampling
frame, study staff approached each patient consecutively as the patients passed through a
central point in the registration process (weight measurement) until a patient indicated
willingness to participate in the study. The recruiting staff member then obtained written
informed consent from the interested patient and completed the first part of data collection.
The patient would then complete the second part of data collection with a second staff
member while the recruiting staff member resumed approaching patients consecutively at
registration.
Instruments
PHQ-9—The PHQ-9 is a widely used 9-item screener for depression that assesses the
presence within the past two weeks of the 9 core symptoms of depression as specified by the
DSM-IV.11 Each symptom is rated as being present none of the time, a few days, more than
half the days, or nearly every day in the past two weeks. The PHQ-9 total score can range
from 0–27, with a score of 10 or above being considered in many settings as an indication of
a likely depressive disorder.
In order to assess any needed adaptations of the wording of the PHQ-9 for use in our setting,
we conducted four focus groups with hospital patients and family members from our study
site. Groups were separated by gender and religion (Christian and non-Christian). Study
staff trained in qualitative methods led the focus groups, which were audio-recorded and
transcribed for content analysis. The analysis suggested minor wording changes to two of
the questions and optional clarifications (that were read only if the original question was not
understood) for six additional questions.
Reference standard: CIDI—Diagnoses of major depression were established with the
reference standard Composite International Diagnostic Instrument (CIDI) from the World
Health Organization. The CIDI is a lay-administered diagnostic instrument whose
performance has been validated widely in multiple international settings, including HIV
settings.12,13 The CIDI is a comprehensive, fully structured interview designed to be used by
trained lay interviewers for the assessment of mental disorders in epidemiological and cross-
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cultural studies as well as for clinical and research purposes. We used the World Mental
Health Survey Initiative Version of the CIDI (WMH-CIDI), which allows the assessment of
mental disorders according to the definitions and criteria of ICD-10 and DSM-IV. The
diagnostic section of the interview expands upon earlier versions of the CIDI by adding
detailed questions about disorder severity, impairment, service use, and treatment, and has
improved generalizability with increased involvement of less wealthy countries. This
version has been successfully used in Sub-Saharan Africa (Nigeria).14
Procedures
After consent, participants completed the PHQ-9 with one study team member. Given the
low level of literacy in the target population, the PHQ-9 was read to all participants and
responses were recorded on the form by the study team member, who was trained in PHQ-9
administration. Previous studies have found comparable results from interviewer
administration and self-administration of the PHQ-9.15 Participants also provided socio-
demographic information, completed the International HIV Dementia Scale,16 and were
asked whether in the past 6 months they had experienced each of 13 symptoms commonly
associated with HIV infection: new or persistent headaches, fevers, oral pain, white patches
in the mouth, rashes, nausea, trouble with eyes, sinus infection, numbness in the hands or
feet, persistent cough, diarrhea, weight loss, or (for women only) abnormal vaginal
discharge.
Participants then completed the Screening and Depression modules of the CIDI in an in-
person interview with a second study team member who was blinded to the results of the
PHQ-9 screening. The CIDI interviewer was a health care professional who received formal
CIDI training from a WHO-certified trainer. The CIDI interviewer completed regular
supervision and record review with a psychiatrist (BNG) to ensure consistence and accuracy
of diagnoses.
Measures
Based on validation studies of the PHQ-9 in other settings, we defined a positive screen for
depression as a PHQ-9 total score of ≥10.7,17 In sensitivity analyses we also considered
alternative cutoffs of ≥8 and ≥12.
Standard CIDI scoring methodology requires the following components for a lifetime major
depressive episode: a period lasting at least two weeks characterized by at least 5 out of 9
core depressive symptoms, with at least one symptom being either depressed mood or
anhedonia, and representing a change from previous functioning; the symptoms must have
caused clinically significant distress or impairment in social, occupational, or other
important areas of functioning; the symptoms must not be better explained by substance use
or a general medical condition; and the symptoms must not be better explained by
bereavement, or if secondary to bereavement, the episode either must last more than two
months or be characterized by at least one of the following: marked functional impairment,
morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or
psychomotor retardation.
On the CIDI, participants reporting any lifetime major depressive episode (MDE) were
asked if they had experienced any similar episodes in the past year, past 6 months, past
month, and currently. Participants reporting an episode in the past year or more recently
completed a standard depressive severity rating scale called the Quick Inventory of
Depressive Symptoms (QIDS)4 that is embedded within the CIDI. The QIDS total score can
range from 0–27 and has standard categories that correspond to very severe (21–27), severe
(16–20), moderate (11–15), mild (6–10), and no (0–5) depressive symptoms. Participants
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were classified as having a diagnosis of a MDE in the past year, past 6 months, and past
month if they endorsed a depressive episode in those time frames and received a score of 11
or above on the QIDS.
The IHDS was scored according to standard methodology.16 Each of three tasks (motor
speed – number of finger taps in 5 seconds; psychomotor speed – number of sequences of a
pattern of hand movements in 10 seconds; memory-recall – number of words recalled) is
scored on a 0–4 scale, with higher scores indicating better functioning and a maximum
possible score of 12. A score of10 or below is considered a positive screen for possible
dementia.
Statistical analysis
Participant characteristics are described with proportions or with means and standard
deviations (SD). To calculate test characteristics of the PHQ-9 relative to the CIDI, we
ideally would have compared a positive PHQ-9 screen (which references the past two
weeks) to CIDI diagnoses of current MDE. However, the overall prevalence of MDE in the
sample was lower than anticipated and an initial examination of the prevalence of MDE in
different time frames indicated that there were too few cases of current MDE to allow
meaningful estimation of sensitivity. We therefore made the decision for the primary
analysis to compare the PHQ-9 to CIDI diagnoses of MDE in the past month, as has been
done in prior studies,18,19 recognizing that the time frames referenced by the two
instruments would differ.
We calculated the sensitivity, specificity, likelihood ratio positive (LR+), and likelihood
ratio negative (LR−) for this comparison. Since positive and negative predictive value (PPV
and NPV) vary by prevalence, we present what the PPV and NPV for a range of different
prevalence values for depression. We examined whether there was evidence that the test
characteristics of the PHQ-9 differed in certain subgroups (gender, HIV physical symptoms,
English proficiency, and dementia score). In secondary analyses, we considered different
thresholds for the PHQ-9 (8, 10, and 12) and different time frames for the CIDI (current
versus past month).
Results
Between May and October, 2010, 461 patients were approached; 48 were not eligible (26
did not speak English well enough to complete study activities, and 22 were >55 years old)
and 13 declined to participate (10 did not have time and 3 wished to consult their spouse
before participating). Informed consent was provided by the remaining 400 participants.
Participants had a median age of 41 years (interquartile range: 34–47 years); 74% were
female, 99% were Christian (religious affiliations were indicated as Muslim by four
participants and traditional by one participant), and 61% had completed only primary
education (Table 1). The self-reported estimated median household daily expenditures were
FCFA 700 (IQR 400–1400) (approximately US $1 [$1–$3]). Participants endorsed a median
of 5 HIV-related symptoms (IQR: 3–6). A majority of participants (83%) met criteria for
possible dementia. More than half of the subjects performed poorly on the memory sub-
scale (54% with a score ≤3 out of 4).
Of 398 individuals with a complete CIDI assessment, 11 (3%) met diagnostic criteria for a
major depressive episode in the past month (Table 2). Of these 11 cases, 3 had a positive
PHQ-9 screen for depression at a cutoff of 10 or above (true positives) (Table 3). Of the 387
participants without a diagnosis of an MDE in the past month, 364 had a negative PHQ-9
screen. Thus the standard PHQ-9 cutoff of 10 or above had a sensitivity of 27% (95% CI: 6–
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61%) and a specificity of 94% (95% CI: 91–96%) relative to an MDE diagnosis on the CIDI
in the past month. These test characteristics correspond to a LR+ of 4.5 and a LR− of 0.8.
In sensitivity analyses, we compared the standard PHQ-9 cutoff score of 10 to current MDE
diagnoses at the time of interview. Four participants (1%) met criteria for a current MDE.
When considering current MDE, the sensitivity of the PHQ-9 was higher than when
considering past-month MDE (50%, 95% CI: 7–93%). Specificity was unchanged at 94%
(95% CI: 91–96%).
Compared to the original time frame of MDE in the past month, use of a lower PHQ-9
cutoff of 8 yielded a slightly higher sensitivity and lower specificity, while use of a higher
PHQ-9 cutoff of 12 yielded a slightly lower sensitivity and higher specificity (Table 3).
Given the low number of cases and the resulting wide uncertainty around the sensitivity
estimate, we do not present a full ROC curve, as ROC estimates would be imprecise.
As PPV and NPV are functions of prevalence as well as sensitivity and specificity, we
illustrate in Figure 1 the PPV and NPV for the observed sensitivity and specificity over a
range of possible prevalence values of MDE. At the MDE prevalence of 3% observed in this
population (indicated by the red vertical line), the PHQ-9 had a PPV of 12% (2–30%) and an
NPV of 98% (96–99%). In a hypothetical population with a higher MDE prevalence of 20%,
the PPV of the PHQ-9 would improve to 53% while the NPV would decline to 84%.
The number of MDE cases was too small to assess whether the sensitivity of the PHQ-9
varied for different subgroups. There was little evidence of variation in specificity by
gender, number of HIV symptoms endorsed, or outcome of the International HIV Dementia
Scale assessment (Table 4).
Discussion
In this population of predominantly low-literacy HIV-infected individuals in Cameroon, an
interviewer-administered PHQ-9 demonstrated high specificity but low sensitivity in
identifying cases of major depressive disorder as measured by the gold standard Composite
International Diagnostic Interview (CIDI). The estimate of PHQ-9 specificity at the standard
cutoff of 10 or above was comparable with other published results from a range of
settings.17 The estimate of sensitivity at the standard cutoff was lower than many previous
studies, especially in primary care populations,17 but was comparable to some studies done
in chronically ill medical populations20 and to a recent large validation study in the
Netherlands that also used the CIDI as its gold standard.19 The sensitivity was imprecisely
estimated because of the small number of MDD cases in this population. As expected, the
PHQ-9 (which asks about symptoms in the past two weeks) demonstrated higher sensitivity
in detecting MDD that was present at the time of interview than MDD diagnoses from any
point in the past month, although conclusions are limited by the low prevalence of cases
available to calculate sensitivity.
The prevalence of depression was somewhat lower in this sample than in other recently
reported studies of HIV-infected individuals in sub-Saharan Africa,21 although the majority
of prevalence estimates from the region have been based on screening instruments rather
than diagnostic instruments. Studies in the region using diagnostic instruments have reported
MDD prevalence estimates ranging from 2.7–34.9%,22–28 with most studies employing the
Mini International Neuropsychiatric Interview.29 The WHO Neuropsychiatric AIDS Study
from the early 1990s, which was the only published study we could identify which used the
CIDI to measure depression among HIV-infected individuals in the region, reported
prevalence estimates in Nairobi, Kenya, of 3.0% and 5.5% in asymptomatic and
symptomatic HIV-infected patients, respectively, and prevalence estimates in Kinshasa,
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Democratic Republic of the Congo, of 0% and 4.4% in asymptomatic and symptomatic
HIV-infected patients.12
Although several studies have considered the internal and construct validity of the PHQ-9 in
sub-Saharan African populations,30,31 including in HIV patients,8 we identified only one
formal validation study from Africa that reported sensitivity and specificity of the PHQ-9
relative to a reference standard diagnostic instrument.7 This validation study compared a
self-administered PHQ-9 to the Mini International Neuropsychiatric Interview (MINI)
among a highly educated sample of Nigerian university students and reported a sensitivity of
85% and specificity of 99%. Although promising, the performance of the PHQ-9 and other
depression screening instruments needs to be better understood in Cameroon and other low-
income countries.
This study's findings should be understood in light of its strengths and limitations. The
generalizability of the present study is enhanced by the consecutive sampling approach,
broad inclusion criteria, and recruitment from a large regional HIV/AIDS treatment center.
The validity of our screening and diagnostic measures of depression was enhanced by
adaptation of the PHQ-9 for use in Cameroon through focus group feedback, rigorous
training of interviewers, regular review of diagnostic decisions by a supervising psychiatrist,
and blinding of the CIDI interviewer to the results of the PHQ-9 screening. Due to the low
level of literacy in the target population, we chose to have the PHQ-9 be interviewer-
administered rather than self-administered. The PHQ-9 was developed as a self-administered
tool and only a small number of studies have validated an interviewer-administered
version.32 Although previous studies have reported consistent performance between self-
administration and interviewer administration of the PHQ-9,15 it is possible that
administration mode in this population affected the estimated test characteristics. For
example, participants may be less likely to report depressive symptoms to an interviewer
than to endorse them on paper, which would be expected to bias the estimate of sensitivity
downward. The prevalence of positive screens for dementia of 83% was higher than in
previous research among HIV-infected patients in Cameroon,33 suggesting some degree of
memory impairment in the study subjects which could also have biased the sensitivity
downward in this interviewer administrated version of the PHQ-9. The estimates of test
characteristics may also have been influenced by the difference in time frames referenced by
the PHQ-9 (past two weeks) and the CIDI (past month), which would also be expected to
bias the estimate of sensitivity downward. Our approach, however, was consistent with18 or
more stringent than19 similar studies using the CIDI as the reference standard.
Insufficient evidence was available in this study to distinguish between the competing
hypotheses described above for the observed low sensitivity of the PHQ-9. Efforts to
identify depression screening protocols with higher sensitivity might focus on (1)
conducting validation studies in larger populations or populations with a higher prevalence
of depression to permit more precise estimation of sensitivity; (2) testing whether mode of
administration affects sensitivity, for example by comparing interviewer administration to
audio computer-assisted self-interview (ACASI); and (3) testing whether medical
comorbidity, and particularly co-occurrence of dementia, affects sensitivity. Given other
reports of low sensitivity of the PHQ-9 in chronically medically ill and non-US
populations,19,20,34,35 additional research should also directly compare various depression
screening instruments to identify which instrument has the best characteristics in a given
population.
In conclusion, the PHQ-9 demonstrated high specificity but apparently low sensitivity at the
standard cutoff in detecting past-month MDD as measured by the CIDI in this sample of
HIV patients receiving ART in an urban center in Cameroon. The high specificity suggests
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that any positive screen will require immediate clinical attention to confirm a diagnosis. On
the other hand, the low estimated sensitivity implies a high false negative rate, suggesting
that methods to increase opportunities for identifying patients with MDD may be useful.
However, sensitivity was extremely imprecisely measured because of the low prevalence of
MDD in the sample. Further research may benefit from identifying higher-prevalence
populations to improve sensitivity estimates, examining the role of administration mode on
PHQ-9 performance, assessing the impact of dementia and other medical comorbidities on
test characteristics, and validating alternative depression screening tools. In general, the
results of this study underline the importance of formative work such as diagnostic
validation studies when applying a depression screening instrument in a new population.
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Figure 1. Positive and negative predictive values of PHQ-9 by depression prevalence
PPV: Positive predictive value. NPV: Negative predictive value.
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Table 1
Characteristics of the overall study population (n=400)
Characteristic n (%) or median (IQR)
Sex
 Male 103 (26)
 Female 297 (74)
Age 41 (34–47)
Religion
 Christian 394 (99)
 Other 5 (1)
Marital status
 Married/cohabitating 137 (34)
 Previously married 178 (44)
 Never married 85 (21)
Education*
 Primary 245 (61)
 Greater than primary 155 (39)
Daily expenditures** US$1 ($1–3)
Village of residence
 Urban 244 (61)
 Rural 156 (39)
HIV symptom score (possible range: 0–13) 5 (3–6)
Dementia score (possible range: 4–12)*** 9 (8–10)
 Negative screen (>10) 66 (17)
 Positive screen (≤10) 333 (83)
IQR: Interquartile range.
*
Primary=6 years or fewer; greater than primary=more than 6 years
**
In US dollars, approximation based on reported weekly expenditures in FCFA (Central Africa CFA francs).
***
Score on the International HIV Dementia Scale screening tool
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Table 2
Comparison of PHQ-9 screening results to depressive diagnosis using CIDI
MDD, past month




CIDI: Composite International Diagnostic Interview. MDD: Major Depressive Disorder.
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Table 3
PHQ-9 screening characteristics at selected cut-off values
Cut-point Sensitivity (95% CI) Specificity (95% CI) LR+ LR−
PHQ-9 ≥8 0.36 (0.11, 0.69) 0.89 (0.86, 0.92) 3.3 0.7
PHQ-9 ≥10 0.27 (0.06, 0.61) 0.94 (0.91, 0.96) 4.5 0.8
PHQ-9 ≥12 0.18 (0.02, 0.52) 0.97 (0.95, 0.98) 6.0 0.8
LR: Likelihood ratio.
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Table 4
Comparison of specificity of PHQ-9 screening between subgroups
Characteristic Prevalence of past-month depression (CIDI) Specificity of PHQ-9 Exact P-value (two-tailed)
Gender
  Male 4% 0.94 (0.87, 0.98)
  Female 2% 0.94 (0.91, 0.97) 1.00
HIV symptom score
  <5 2% 0.96 (0.92, 0.98)
  5+ 4% 0.92 (0.88, 0.96) 0.14
IHDS result
  Positive dementia screen 2% 0.95 (0.92, 0.97)
  Negative dementia screen 5% 0.90 (0.80, 0.96) 0.24
CIDI: Composite International Diagnostic Interview. IHDS: International HIV Dementia Scale
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